2026-06-14T02:29:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89992025-05-09T09:33:09Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16967

00925njm 22002777a 4500 dc Jimenez-Jorge, Silvia author Mateo-Ontañon, Salvador de author Delgado-Sanz, Concepcion author Pozo Sanchez, Francisco author Casas Flecha, Inmaculada author Garcia-Cenoz, Manuel author Castilla Catalán, Jesús author Rodriguez, C author Vega, T author Quinones, C author Martinez, E author Vanrell, Juana María author Gimenez, J author Castrillejo, D author Altzibar, Jone M author Carril, F author Ramos, J M author Serrano, M C author Martinez, A author Torner, Núria author Perez, E author Gallardo, V author Larrauri, Amparo author Spanish Influenza Sentinel Surveillance System author 2015-07-16 We aimed to estimate influenza vaccine effectiveness (VE) against laboratory-confirmed influenza during three influenza seasons (2010/11 to 2012/2013) in Spain using surveillance data and to compare the results with data obtained by the cycEVA study, the Spanish component of the Influenza Monitoring Vaccine Effectiveness (I-MOVE) network. We used the test-negative case–control design, with data from the Spanish Influenza Sentinel Surveillance System (SISS) or from the cycEVA study. Cases were laboratory-confirmed influenza patients with the predominant influenza virus of each season, and controls were those testing negative for any influenza virus. We calculated the overall and age-specific adjusted VE. Although the number of patients recorded in the SISS was three times higher than that in the cycEVA study, the quality of information for important variables, i.e. vaccination status and laboratory results, was high in both studies. Overall, the SISS and cycEVA influenza VE estimates were largely similar during the study period. For elderly patients (> 59 years), the SISS estimates were slightly lower than those of cycEVA, and estimates for children (0–14 years) were higher using SISS in two of the three seasons studied. Enhancing the SISS by collecting the date of influenza vaccination and reducing the percentage of patients with incomplete information would optimise the system to provide reliable annual influenza VE estimates to guide influenza vaccination policies. Euro Surveill. 2015 Jul 16;20(28). pii: 21187. 10.2807/1560-7917.es2015.20.28.21187 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin http://hdl.handle.net/20.500.13003/17546 26212144 L605345973 2-s2.0-84937720799 http://hdl.handle.net/20.500.12105/8999 Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data